Engel A M, Finkelstein A E
Haemostasis. 1981;10(4):203-14. doi: 10.1159/000214405.
The activity of the inhibitor of activated Stuart factor (anti-Xa) was evaluated together with the activity of the antiactivator of plasminogen (antiplasminogen) and the amount and nature of the fibrinogen/fibrin degradation products (FDP), as indicators of the existence of the risk for hypercoagulability in patients with acute and recent myocardial infarction (AMI and RMI, respectively). The activity of anti-Xa was diminished in the AMI group with a p less than 0.001. The antiplasminogen activity was increased in both groups with a p less than 0.001; on the other hand, the amount of FDP was increased in the AMI patients and they were of the 'early' type, while in the RMI group the increase was not as marked, but the FDP were of the 'late' type. In both groups the euglobulin lysis time was very prolonged, while the plasminogen did not vary significantly. The tests described appear to be valuable tools for studying the status of the cardiovascular system during cardiac rehabilitation.
作为急性心肌梗死（分别为AMI和RMI）患者发生高凝风险的指标，同时评估活化的斯图尔特因子抑制剂（抗Xa）的活性、纤溶酶原抗激活剂（抗纤溶酶原）的活性以及纤维蛋白原/纤维蛋白降解产物（FDP）的数量和性质。AMI组中抗Xa的活性降低，p值小于0.001。两组中抗纤溶酶原活性均升高，p值小于0.001；另一方面，AMI患者的FDP数量增加，且为“早期”类型，而RMI组的增加不明显，但FDP为“晚期”类型。两组的优球蛋白溶解时间均非常延长，而纤溶酶原无显著变化。所描述的这些检测似乎是研究心脏康复期间心血管系统状况的有价值工具。
